PL2225233T3 - Pochodna oksadiazolu aktywna wobec sfingozyno-1-fosforanu (S1P) - Google Patents
Pochodna oksadiazolu aktywna wobec sfingozyno-1-fosforanu (S1P)Info
- Publication number
- PL2225233T3 PL2225233T3 PL08863529T PL08863529T PL2225233T3 PL 2225233 T3 PL2225233 T3 PL 2225233T3 PL 08863529 T PL08863529 T PL 08863529T PL 08863529 T PL08863529 T PL 08863529T PL 2225233 T3 PL2225233 T3 PL 2225233T3
- Authority
- PL
- Poland
- Prior art keywords
- sphingosine
- phosphate
- oxadiazole derivative
- derivative active
- active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0725101.0A GB0725101D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
| EP08863529.7A EP2225233B1 (en) | 2007-12-21 | 2008-12-19 | Oxadiazole derivative active on sphingosine-1-phosphate (s1p) |
| PCT/EP2008/067963 WO2009080724A1 (en) | 2007-12-21 | 2008-12-19 | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2225233T3 true PL2225233T3 (pl) | 2014-01-31 |
Family
ID=39048651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08863529T PL2225233T3 (pl) | 2007-12-21 | 2008-12-19 | Pochodna oksadiazolu aktywna wobec sfingozyno-1-fosforanu (S1P) |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8278324B2 (pl) |
| EP (2) | EP2225233B1 (pl) |
| JP (1) | JP2011506568A (pl) |
| KR (1) | KR20100108568A (pl) |
| CN (1) | CN101945864A (pl) |
| AU (1) | AU2008339987B2 (pl) |
| BR (1) | BRPI0821069A2 (pl) |
| CA (1) | CA2710067A1 (pl) |
| CO (1) | CO6290688A2 (pl) |
| CR (1) | CR11578A (pl) |
| DK (1) | DK2225233T3 (pl) |
| DO (1) | DOP2010000187A (pl) |
| EA (1) | EA018637B1 (pl) |
| ES (1) | ES2431795T3 (pl) |
| GB (1) | GB0725101D0 (pl) |
| HR (1) | HRP20131053T1 (pl) |
| IL (1) | IL206278A0 (pl) |
| MA (1) | MA31922B1 (pl) |
| NZ (1) | NZ585994A (pl) |
| PL (1) | PL2225233T3 (pl) |
| PT (1) | PT2225233E (pl) |
| UA (1) | UA102539C2 (pl) |
| WO (1) | WO2009080724A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| EP2481740B1 (en) * | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| HUE039931T2 (hu) | 2013-02-20 | 2019-02-28 | Lg Chemical Ltd | Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények |
| CN110831593A (zh) * | 2017-06-14 | 2020-02-21 | 特维娜有限公司 | 用于调节s1p1活性的化合物及其使用方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| EP1549640A4 (en) * | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
| MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| CN102174042B (zh) | 2003-05-19 | 2013-09-18 | Irm有限责任公司 | 免疫抑制剂化合物和组合物 |
| EP1628967B1 (en) * | 2003-05-19 | 2014-04-09 | Irm Llc | Immunosuppressant compounds and compositions |
| AU2004240649A1 (en) * | 2003-05-19 | 2004-12-02 | Irm, Llc | Immunosuppressant compounds and compositions |
| US7605171B2 (en) * | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | S1p受容体結合能を有する化合物およびその用途 |
| CA2583681A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| CA2591399C (en) * | 2004-12-13 | 2014-05-20 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
| WO2006100633A1 (en) * | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS |
| WO2006115188A1 (ja) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | ヘテロ環化合物 |
| US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| CN101291908A (zh) * | 2005-08-23 | 2008-10-22 | Irm责任有限公司 | 免疫抑制剂化合物和组合物 |
| EP2003132B1 (en) * | 2006-04-03 | 2014-03-05 | Astellas Pharma Inc. | Oxadiazole derivatives as S1P1 agonists |
| JP2010510251A (ja) * | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン=1−燐酸受容体活性を有するベンゾシクロヘプチルアナログ |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
-
2007
- 2007-12-21 GB GBGB0725101.0A patent/GB0725101D0/en not_active Ceased
-
2008
- 2008-12-19 BR BRPI0821069-1A patent/BRPI0821069A2/pt not_active IP Right Cessation
- 2008-12-19 KR KR1020107016169A patent/KR20100108568A/ko not_active Ceased
- 2008-12-19 DK DK08863529.7T patent/DK2225233T3/da active
- 2008-12-19 EP EP08863529.7A patent/EP2225233B1/en active Active
- 2008-12-19 NZ NZ585994A patent/NZ585994A/en not_active IP Right Cessation
- 2008-12-19 PL PL08863529T patent/PL2225233T3/pl unknown
- 2008-12-19 EP EP13182453.4A patent/EP2746254A3/en not_active Withdrawn
- 2008-12-19 JP JP2010538740A patent/JP2011506568A/ja not_active Ceased
- 2008-12-19 AU AU2008339987A patent/AU2008339987B2/en not_active Ceased
- 2008-12-19 UA UAA201009200A patent/UA102539C2/ru unknown
- 2008-12-19 EA EA201070781A patent/EA018637B1/ru not_active IP Right Cessation
- 2008-12-19 WO PCT/EP2008/067963 patent/WO2009080724A1/en not_active Ceased
- 2008-12-19 PT PT88635297T patent/PT2225233E/pt unknown
- 2008-12-19 ES ES08863529T patent/ES2431795T3/es active Active
- 2008-12-19 US US12/747,191 patent/US8278324B2/en not_active Expired - Fee Related
- 2008-12-19 HR HRP20131053AT patent/HRP20131053T1/hr unknown
- 2008-12-19 CA CA2710067A patent/CA2710067A1/en not_active Abandoned
- 2008-12-19 CN CN2008801273526A patent/CN101945864A/zh active Pending
-
2010
- 2010-02-24 US US12/711,318 patent/US20100152235A1/en not_active Abandoned
- 2010-06-10 IL IL206278A patent/IL206278A0/en unknown
- 2010-06-16 MA MA32924A patent/MA31922B1/fr unknown
- 2010-06-18 DO DO2010000187A patent/DOP2010000187A/es unknown
- 2010-06-21 CO CO10074471A patent/CO6290688A2/es active IP Right Grant
- 2010-07-21 CR CR11578A patent/CR11578A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO6290688A2 (es) | 2011-06-20 |
| EP2746254A3 (en) | 2014-10-15 |
| KR20100108568A (ko) | 2010-10-07 |
| MA31922B1 (fr) | 2010-12-01 |
| EP2225233B1 (en) | 2013-09-04 |
| JP2011506568A (ja) | 2011-03-03 |
| AU2008339987A1 (en) | 2009-07-02 |
| CA2710067A1 (en) | 2009-07-02 |
| GB0725101D0 (en) | 2008-01-30 |
| HRP20131053T1 (hr) | 2013-12-06 |
| DK2225233T3 (da) | 2013-10-14 |
| EA201070781A1 (ru) | 2010-12-30 |
| WO2009080724A1 (en) | 2009-07-02 |
| EP2746254A2 (en) | 2014-06-25 |
| NZ585994A (en) | 2012-02-24 |
| PT2225233E (pt) | 2013-11-22 |
| CN101945864A (zh) | 2011-01-12 |
| ES2431795T3 (es) | 2013-11-28 |
| CR11578A (es) | 2010-09-23 |
| EA018637B1 (ru) | 2013-09-30 |
| US20100273827A1 (en) | 2010-10-28 |
| DOP2010000187A (es) | 2010-08-15 |
| US8278324B2 (en) | 2012-10-02 |
| US20100152235A1 (en) | 2010-06-17 |
| EP2225233A1 (en) | 2010-09-08 |
| BRPI0821069A2 (pt) | 2015-06-16 |
| AU2008339987B2 (en) | 2013-03-21 |
| UA102539C2 (ru) | 2013-07-25 |
| IL206278A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL206235A0 (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
| IL206278A0 (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
| EP2141990A4 (en) | ACTIVE COMPOUNDS ON 11BETA-HSD1 | |
| JP1322466S (en) | An earphone | |
| ZA201104423B (en) | Oxadiazole derivatives | |
| KR101608166B9 (ko) | 펌프 카세트 | |
| PL2520575T3 (pl) | Związek 1,3,4-oksadiazolo-2-karboksyamidowy | |
| PL2003132T3 (pl) | Pochodne oksadiazolu jako agoniści S1P1 | |
| IL200870A0 (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | |
| IL196101A0 (en) | C-phenyl 1-thioglucitol compound | |
| EP2156296A4 (en) | STORAGE IN CLUSTERS USING UNDER-SEGMENTATION | |
| IL207757A0 (en) | Hererocyclic compound | |
| EP2355898A4 (en) | HOUSING STRUCTURE FOR A MEDICAL IMPLANT COMPRISING A MONOLITHIC SUBSTRATE | |
| GB0716026D0 (en) | An inhalable medicament | |
| WO2009085272A3 (en) | Improved medical devices | |
| PL2154968T3 (pl) | Kombinacje grzybobójczych substancji czynnych | |
| IL199771A0 (en) | Active substance combination | |
| IL224071B (en) | 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors | |
| GB0722340D0 (en) | Sphingosine-1-phosphate (S1P) receptor compounds | |
| IL197008A0 (en) | Improved storage performance | |
| HK1142071A (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
| TWI346662B (en) | Oxadiazole compounds | |
| GB0708415D0 (en) | Insert for high stress connection | |
| ZA200906256B (en) | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | |
| HK1133371A (en) | 11beta-hsd1 active compounds |